Skip to main content

Loading market data...

KNSA

Kiniksa Pharmaceuticals International, plc

NASDAQ • United states

$80.19

-$2.98

(-3.58%)

Source: Yahoo Finance · Quote time Oct 21, 2026 17:47 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Kiniksa Pharmaceuticals International, plc (KNSA)

Unavailable

Quotes may be delayed

$6.26B

Market Cap

507,942

Volume

85.6

P/E Ratio

Unavailable

Div Yield

Kiniksa Pharmaceuticals International, plc Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 23 OLD BOND STREET, FLOOR 3, LONDON, X0
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

29 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Kiniksa Pharmaceuticals International, plc.

28 Jul 2026

Kiniksa Pharmaceuticals International, plc filed Form 10-Q

Kiniksa Pharmaceuticals International, plc submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

28 Jul 2026

Kiniksa Pharmaceuticals International, plc reported Operating or financial results

Kiniksa Pharmaceuticals International, plc filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

29 May 2026

Kiniksa Pharmaceuticals International, plc reported Shareholder voting results

Kiniksa Pharmaceuticals International, plc filed an 8-K covering shareholder voting results.

26 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Kiniksa Pharmaceuticals International, plc.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$189.95M

Total assets (USD)$825.28M

Total liabilities (USD)$219.59M

Shareholders' equity (USD)$605.69M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 31 Mar 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2026	$214.27M	$29.27M	$22.59M	$0.27	10-Q · 28 Apr 2026
Q4 2025	$202.13M	$19.77M	$14.20M	Unavailable	10-K · 24 Feb 2026
Q3 2025	$180.86M	$24.02M	$18.44M	$0.23	10-Q · 28 Oct 2025
Q2 2025	$156.80M	$20.16M	$17.83M	$0.23	10-Q · 29 Jul 2025
Q1 2025	$137.79M	$13.27M	$8.54M	$0.11	10-Q · 29 Apr 2025
Q4 2024	$122.54M	−$19.30M	−$8.89M	Unavailable	10-K · 25 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $96.57

20.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

7

⏸️

Hold

0

📉

Sell

0

7 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 17:47 UTC Targets range 87.00–107.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

3

Sep 2026

Megna Michael R

CHIEF ACCOUNTING OFFICER

Open-market sale

$80.30 per share

4,600 shares

1

Sep 2026

Ragosa Mark

CHIEF FINANCIAL OFFICER

Option exercise

Unavailable per share

9,104 shares

1

Sep 2026

Ragosa Mark

CHIEF FINANCIAL OFFICER

Tax withholding

$79.28 per share

4,404 shares

1

Sep 2026

Patel Sanj K

Director, CHAIRMAN & CEO

Option exercise

Unavailable per share

31,318 shares

1

Sep 2026

Patel Sanj K

Director, CHAIRMAN & CEO

Tax withholding

$79.28 per share

15,144 shares

1

Sep 2026

Patel Sanj K

Director, CHAIRMAN & CEO

Option exercise

Unavailable per share

31,318 shares

1

Sep 2026

Patel Sanj K

Director, CHAIRMAN & CEO

Tax withholding

$79.28 per share

15,144 shares

1

Sep 2026

Paolini John F.

CHIEF MEDICAL OFFICER

Option exercise

Unavailable per share

8,328 shares

1

Sep 2026

Paolini John F.

CHIEF MEDICAL OFFICER

Tax withholding

$79.28 per share

4,029 shares

1

Sep 2026

Moat Ross

CHIEF OPERATING OFFICER

Option exercise

Unavailable per share

8,285 shares

Top Shareholders

Fmr Llc

6,971,361 shares

2.164% change

6/30/2026

Rubric Capital Management Lp

3,999,800 shares

6.661% change

6/30/2026

Vanguard Group Inc

3,112,937 shares

1.626% change

12/31/2025

Baker Bros. Advisors Lp

2,834,643 shares

0.297% change

6/30/2026

Blackrock, Inc.

2,739,615 shares

462.853% change

6/30/2026

Tang Capital Management Llc

2,259,889 shares

0% change

6/30/2026

Vanguard Portfolio Management Llc

1,911,335 shares

8.213% change

6/30/2026

Vanguard Capital Management Llc

1,360,840 shares

2.081% change

6/30/2026

Morgan Stanley

1,011,143 shares

1.339% change

6/30/2026

Arrowstreet Capital, Limited Partnership

957,514 shares

7.265% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 17:48 UTC· 12 hours ago

Research coverage and investment tools

Kiniksa Pharmaceuticals International, plc (KNSA) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$80.19 on 21 Oct 2026. That is 92% of the way from its 52-week low of US$35.20 to its 52-week high of US$84.06. Its market capitalisation was US$6.26 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2026	$214.27M	$29.27M	$22.59M	$0.27	—	13.7%	$50.04M	10-Q · 28 Apr 2026 (opens in a new tab)
Q4 2025	$202.13M	$19.77M	$14.20M	Unavailable	—	9.8%	$53.26M	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$180.86M	$24.02M	$18.44M	$0.23	—	13.3%	$33.01M	10-Q · 28 Oct 2025 (opens in a new tab)
Q2 2025	$156.80M	$20.16M	$17.83M	$0.23	—	12.9%	$27.93M	10-Q · 29 Jul 2025 (opens in a new tab)
Q1 2025	$137.79M	$13.27M	$8.54M	$0.11	—	9.6%	$22.23M	10-Q · 29 Apr 2025 (opens in a new tab)
Q4 2024	$122.54M	−$19.30M	−$8.89M	Unavailable	—	-15.7%	$18.58M	10-K · 25 Feb 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/28/2026	$0.30	$0.30	0.0%
Mar 2026	4/28/2026	$0.27	$0.18	+50.0%
Dec 2025	2/24/2026	$0.17	$0.29	-41.4%
Sep 2025	10/28/2025	$0.23	$0.33	-30.3%

Cash and equivalents: $189.95M
Total assets: $825.28M
Total liabilities: $219.59M
Shareholders' equity: $605.69M

SCHEDULE 13G · 29 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Kiniksa Pharmaceuticals International, plc.
10-Q · 28 Jul 2026

Kiniksa Pharmaceuticals International, plc filed Form 10-Q (opens in a new tab)

Kiniksa Pharmaceuticals International, plc submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 28 Jul 2026

Kiniksa Pharmaceuticals International, plc reported Operating or financial results (opens in a new tab)

Kiniksa Pharmaceuticals International, plc filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 29 May 2026

Kiniksa Pharmaceuticals International, plc reported Shareholder voting results (opens in a new tab)

Kiniksa Pharmaceuticals International, plc filed an 8-K covering shareholder voting results.
SCHEDULE 13D/A · 26 May 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Kiniksa Pharmaceuticals International, plc.

Insider	Date	Transaction	Shares	Average price	Filing
Megna Michael R CHIEF ACCOUNTING OFFICER	3 Sep 2026	Open-market sale (S)	−4,600	$80.30	Form 4 (opens in a new tab)
Ragosa Mark CHIEF FINANCIAL OFFICER	1 Sep 2026	Option exercise (M)	+9,104	—	Form 4 (opens in a new tab)
Ragosa Mark CHIEF FINANCIAL OFFICER	1 Sep 2026	Tax withholding (F)	−4,404	$79.28	Form 4 (opens in a new tab)
Patel Sanj K Director, CHAIRMAN & CEO	1 Sep 2026	Option exercise (M)	+31,318	—	Form 4 (opens in a new tab)
Patel Sanj K Director, CHAIRMAN & CEO	1 Sep 2026	Tax withholding (F)	−15,144	$79.28	Form 4 (opens in a new tab)
Patel Sanj K Director, CHAIRMAN & CEO	1 Sep 2026	Option exercise (M)	+31,318	—	Form 4 (opens in a new tab)
Patel Sanj K Director, CHAIRMAN & CEO	1 Sep 2026	Tax withholding (F)	−15,144	$79.28	Form 4 (opens in a new tab)
Paolini John F. CHIEF MEDICAL OFFICER	1 Sep 2026	Option exercise (M)	+8,328	—	Form 4 (opens in a new tab)
Paolini John F. CHIEF MEDICAL OFFICER	1 Sep 2026	Tax withholding (F)	−4,029	$79.28	Form 4 (opens in a new tab)
Moat Ross CHIEF OPERATING OFFICER	1 Sep 2026	Option exercise (M)	+8,285	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Fmr Llc	6/30/2026	6,971,361	2.164%
Rubric Capital Management Lp	6/30/2026	3,999,800	6.661%
Vanguard Group Inc	12/31/2025	3,112,937	1.626%
Baker Bros. Advisors Lp	6/30/2026	2,834,643	0.297%
Blackrock, Inc.	6/30/2026	2,739,615	462.853%
Tang Capital Management Llc	6/30/2026	2,259,889	0%
Vanguard Portfolio Management Llc	6/30/2026	1,911,335	8.213%
Vanguard Capital Management Llc	6/30/2026	1,360,840	2.081%
Morgan Stanley	6/30/2026	1,011,143	1.339%
Arrowstreet Capital, Limited Partnership	6/30/2026	957,514	7.265%

Previous close: 83.17 USD
Day range: 78.74 – 84.06 USD
52-week range: 35.20 – 84.06 USD
Volume: 507,942
Market cap: $6.26B
Average volume: 535,823
P/E ratio: 85.6
EPS (FY 2025, diluted): 0.75 USD
Shares outstanding: 78.02M
Beta (5Y monthly): 0.12

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 17:47 UTC· 12 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 01:36 UTC· 4 hours ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for KNSA yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.